Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?
Clin Neurol Neurosurg
; 208: 106887, 2021 Sep.
Article
in English
| MEDLINE | ID: covidwho-1433072
ABSTRACT
We report a case of Guillain-Barré syndrome (GBS) following the first dose of Oxford/AstraZeneca COVID-19 vaccine with papilledema as atypical onset. As the COVID-19 vaccination campaign progresses worldwide, GBSs vaccine-related have been increasingly reported. After reviewing the available literature, considering the annual incidence of GBS, in this historical moment, the public health systems cannot afford an unjustified distrust in vaccines, caused by misinterpretation of epidemiological data. Nonetheless, it is important for clinicians to promptly recognize neurological complications potentially associated with COVID-19 vaccinations and report them to pharmacovigilance agencies.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Guillain-Barre Syndrome
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Case report
/
Observational study
Topics:
Vaccines
Limits:
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Clin Neurol Neurosurg
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS